

Date 09/12/2025
Your Ref
Our Ref 10844

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – UROTHELIAL CANCER

I write in response to your request for information in relation to Urothelial cancer.

Question:

1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Answer:

Our data is grouped in such a way that we cannot search specifically for Urothelial cancer. Data in questions 1 and 2 are for Upper Tract TCC and bladder cancer patients between 01/08/2025 & 31/10/2025.

Name of treatment	Number of patients
Atezolizumab (Tecentriq)	0
Avelumab (Bavencio)	5 or fewer
Carboplatin single agent or in any other combination	6
Carboplatin with Gemcitabine	6
Carboplatin with Gemcitabine + Avelumab (Bavencio)	0
Carboplatin with Paclitaxel	0
Cisplatin single agent or in any other combination	9
Cisplatin with Gemcitabine	9
Cisplatin with Gemcitabine + Nivolumab (Opdivo)	0
Cisplatin with Gemcitabine + Avelumab (Bavencio)	0
Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)	0

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

Nivolumab (Opdivo)	5 or fewer
Pembrolizumab (Keytruda)	10
Other active systemic anti-cancer therapy	5 or fewer
Palliative care only	Data Not Available
Erdafitinib	0

Question:

2. How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies

Answer:

Our data is grouped in such a way that we cannot search specifically for Urothelial cancer. Data in questions 1 and 2 are for Upper Tract TCC and bladder cancer patients between 01/08/2025 & 31/10/2025.

Name of treatment	Number of patients
Carboplatin single agent or in any other combination	5 or fewer
Carboplatin with Gemcitabine	5 or fewer
Carboplatin with Gemcitabine + Avelumab (Bavencio)	0
Carboplatin with Paclitaxel	0
Cisplatin single agent or in any other combination	7
Cisplatin with Gemcitabine	7
Cisplatin with Gemcitabine + Avelumab (Bavencio)	0

Question:

3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Answer:

Full Title	Recruited
DISCUS, A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.	11
ModiFY, A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with	6

Breast, Head and Neck, Ovarian, or Renal Cancer.	
GUSTO, Gene expression subtypes of Urothelial cancer: Stratified Treatment and Oncological outcomes	0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
 Cc: Chief Executive